Sacramento News-Online

Diffuse Large B-cell Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis Report

 Breaking News
  • No posts were found

Diffuse Large B-cell Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis Report

July 01
18:08 2021
Diffuse Large B-cell Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis Report

DelveInsight Business Research LLP
“Diffuse Large B-cell Lymphoma (DLBCL) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma (DLBCL) Market.

Diffuse Large B-cell Lymphoma (DLBCL) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma (DLBCL) Market.

The assessment part of the report embraces in-depth Diffuse Large B-cell Lymphoma (DLBCL) commercial assessment and clinical assessment of the Diffuse Large B-cell Lymphoma (DLBCL) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Large B-cell Lymphoma (DLBCL) collaborations, licensing mergers, and acquisition, funding, designations, and other product-related details.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight

Diffuse Large B-cell Lymphoma (DLBCL) Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) type that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal centre & post germinal centre B-cells.

Diffuse Large B-cell Lymphoma Emerging Therapy Assessment:

There are many companies involved in the development of various therapies for the frontline, second line (transplant-eligible and transplant-ineligible), and subsequent R/R patients with DLBCL such as Acerta Pharma BV/ Astrazeneca, Seattle Genetics/Takeda, ADC Therapeutics, Morphosys/Incyte, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer, Janssen/Pharmacyclics and others.

Diffuse Large B-cell Lymphoma (DLBCL) Key Companies:

  1. Acerta Pharma BV/ Astrazeneca

  2. Genmab and AbbVie

  3. MorphoSys AG

  4. TG Therapeutics

  5. Seattle Genetics/Takeda)

  6. ADC Therapeutics

  7. TG Therapeutics

  8. Celgene/Juno Therapeutics

Diffuse Large B-cell Lymphoma (DLBCL) Therapies covered in the report include:

  1. Acalabrutinib 

  2. Epcoritamab

  3. Tafasitamab

  4. Ublituximab+Umbralisib

  5. Brentuximab Vedotin

  6. Loncastuximab Tesirine

  7. Ublituximab+Umbralisib

  8. JCAR017

Report Highlights:

  1. A better understanding of disease pathogenesis contributes to developing novel therapeutics for Diffuse Large B-cell Lymphoma (DLBCL).

  2. In the coming years, the Diffuse Large B-cell Lymphoma (DLBCL) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, expanding the size of the market to enable the drug manufacturers to penetrate more into the market.

  3. The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Large B-cell Lymphoma (DLBCL) Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  4. A detailed portfolio of major pharma players who are involved in fueling the Diffuse Large B-cell Lymphoma (DLBCL) treatment market. Several potential therapies for Diffuse Large B-cell Lymphoma (DLBCL) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Diffuse Large B-cell Lymphoma (DLBCL) market size in the coming years. 

  5. Our in-depth analysis of the Diffuse Large B-cell Lymphoma (DLBCL) pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Table of Contents

  1. Report Introduction

  2. Diffuse Large B-cell Lymphoma (DLBCL)

  3. Diffuse Large B-cell Lymphoma (DLBCL) Current Treatment Patterns

  4. Diffuse Large B-cell Lymphoma (DLBCL) – DelveInsight’s Analytical Perspective

  5. Therapeutic Assessment

  6. Diffuse Large B-cell Lymphoma (DLBCL) Late Stage Products (Phase-III)

  7. Diffuse Large B-cell Lymphoma (DLBCL) Mid Stage Products (Phase-II)

  8. Early Stage Products (Phase-I)

  9. Pre-clinical Products and Discovery Stage Products

  10. Inactive Products

  11. Dormant Products

  12. Diffuse Large B-cell Lymphoma (DLBCL) Discontinued Products

  13. Diffuse Large B-cell Lymphoma (DLBCL) Product Profiles

  14. Diffuse Large B-cell Lymphoma (DLBCL) Key Companies

  15. Diffuse Large B-cell Lymphoma (DLBCL) Key Products

  16. Dormant and Discontinued Products

  17. Diffuse Large B-cell Lymphoma (DLBCL) Unmet Needs

  18. Diffuse Large B-cell Lymphoma (DLBCL) Future Perspectives

  19. Diffuse Large B-cell Lymphoma (DLBCL) Analyst Review 

  20. Appendix

  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary.

Related Reports: 

Diffuse Large B-cell Lymphoma (DLBCL) Market

DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) Market size and shares analysis for the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Diffuse Large B-cell Lymphoma (DLBCL) Epidemiology

DelveInsight’s Diffuse Large B-cell Lymphoma (DLBCL) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Diffuse Large B-cell Lymphoma (DLBCL) in the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/